# AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

> **NCT01065662** · PHASE1 · COMPLETED · sponsor: **Susana M. Campos, MD** · enrollment: 11 (actual)

## Conditions studied

- Endometrial Cancer
- Ovarian Cancer
- Cervical Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** temsirolimus
- **DRUG:** cediranib

## Key facts

- **NCT ID:** NCT01065662
- **Lead sponsor:** Susana M. Campos, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-09
- **Final completion:** 2021-03
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065662, "AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01065662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*